{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Teofilo E"],"funding":["Bristol-Myers Squibb (France)"],"pagination":["17-28"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4975100"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["17(1)"],"pubmed_abstract":["<h4>Background</h4>Boosted protease inhibitors (PIs), including ritonavir-boosted atazanavir (ATV/r), are a recommended option for the initial treatment of HIV-1 infection based upon clinical trial data; however, long-term real-life clinical data are limited.<h4>Objective</h4>We evaluated the long-term use of ATV/r as a component of antiretroviral combination therapy in the real-life setting in the REMAIN study.<h4>Methods</h4>This was an observational cohort study conducted at sites across Germany, Portugal, and Spain. Retrospective historical and prospective longitudinal follow-up data were extracted every six months from medical records of HIV-infected treatment-naïve patients aged ≥ 18 years initiating a first-line ATV/r-containing regimen.<h4>Results</h4>Eligible patients (n = 517) we"],"journal":["HIV clinical trials"],"pubmed_title":["Long-Term Efficacy, Tolerability, and Renal Safety of Atazanavir/Ritonavir-based Antiretroviral Therapy in a Cohort of Treatment-Naive Patients with HIV-1 Infection: the REMAIN Study."],"pmcid":["PMC4975100"],"funding_grant_id":["Not applicable"],"pubmed_authors":["Muller M","Jimenez-Exposito MJ","de Vilanova A","Karcher H","Teofilo E","Germano I","Freiwald M","Antela A","Mocho L","Gonzalez EO","Jessen H","de Suso MT","Pernia AT","Lauenroth-Mai E","Moreno Guillen S","Barros C","de Almeida J","Revuelta JA","Liano JP","Valente C","REMAIN study group","Vieira R","Fernandez PE","Santos C","Cid JF","Tavares L","Golz J","Schlote F","Mauss S","Aleixo MJ","Almeida L","Stoehr A","Gonzalez JS","Rocha-Pereira N","Serrao R","Schnaitmann E","Mayr C","Baumgarten A","Sanmartin LF","Santos J","Freud HK","Kern WV","Mansinho K","Meurer A","Sierra JO","Garcia JE","Comerma ED","Jimenez MC","Ameida I","Sala BC","Ferrer VF","Stellbrink HJ","Turmstraße P","Schuster D","Urbano J","Pedrol PD","Knechten H","Vera J","Aldeguer JL","de Orta G","Perez DG","Kuhlmann B","Cordes C","Audebert F","Rausch M","Oliveira C","Roxo F"],"additional_accession":[]},"is_claimable":false,"name":"Long-Term Efficacy, Tolerability, and Renal Safety of Atazanavir/Ritonavir-based Antiretroviral Therapy in a Cohort of Treatment-Naive Patients with HIV-1 Infection: the REMAIN Study.","description":"<h4>Background</h4>Boosted protease inhibitors (PIs), including ritonavir-boosted atazanavir (ATV/r), are a recommended option for the initial treatment of HIV-1 infection based upon clinical trial data; however, long-term real-life clinical data are limited.<h4>Objective</h4>We evaluated the long-term use of ATV/r as a component of antiretroviral combination therapy in the real-life setting in the REMAIN study.<h4>Methods</h4>This was an observational cohort study conducted at sites across Germany, Portugal, and Spain. Retrospective historical and prospective longitudinal follow-up data were extracted every six months from medical records of HIV-infected treatment-naïve patients aged ≥ 18 years initiating a first-line ATV/r-containing regimen.<h4>Results</h4>Eligible patients (n = 517) we","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016 Feb","modification":"2025-04-25T19:00:48.156Z","creation":"2019-03-27T02:20:03Z"},"accession":"S-EPMC4975100","cross_references":{"pubmed":["26899539"],"doi":["10.1080/15284336.2015.1112494"]}}